Cantor Fitzgerald just named Rocket Lab the only listed stock that can challenge SpaceX at scale, but the path to a $122 price target runs through an unflown rocket and a multibillion-dollar acquisition still waiting to close.<\/p>\n
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.<\/p>\n
Cantor Fitzgerald analyst Andres Sheppard reiterated an Overweight rating and $122.00 price target on Rocket Lab\u00a0(NASDAQ:RKLB<\/a> | RKLB Price Prediction<\/a>), calling the current level an attractive entry point ahead of the Neutron rocket\u2019s debut. The firm argues Neutron is uniquely positioned to become the only viable alternative and most direct commercial competitor to SpaceX\u2019s Falcon 9 once operational. For long-term investors, the call frames Rocket Lab stock as the clearest listed proxy for the commercial space buildout.<\/p>\n Ticker RKLB Inside the Cantor Fitzgerald Thesis<\/p>\n Sheppard\u2019s bullish stance follows Rocket Lab\u2019s September 15 announcement of secured funding for the Iridium acquisition. Cantor models the combined company will double annual revenue once the deal closes, cementing an end-to-end space platform spanning launch, satellites and services. On Neutron, management is targeting an average selling price of $50 million to $55 million per launch and up to 20 launches per engine, with first flight targeted for later this year.<\/p>\n Rocket Lab by the Numbers<\/p>\n Q2 FY26 revenue reached a record $234.07 million, up 62.0% year-over-year, with product revenues nearly doubling. Non-GAAP gross margin expanded to 41.5%, and backlog grew 137% to $2.36 billion, including more than 90 launches. CEO Peter Beck highlighted \u201cmore than $1 billion in new contracts across launch and space systems already entered into in Q3\u201d, including a $397 million Flatellite award for the U.S. Space Force SB-AMTI program. Guidance calls for Q3 revenue of $250 million to $265 million.<\/p>\n How It Stacks Up Against SpaceX<\/p>\n Ticker RKLB
\nCompany
\nFirm
\nAction
\nOld Rating
\nNew Rating
\nOld Target
\nNew Target<\/p>\n
\nRocket Lab USA
\nCantor Fitzgerald
\nReiterated
\nOverweight
\nOverweight
\n$122.00
\n$122.00<\/p>\n
\nCompany
\nRating
\nPrice Target<\/p>\n
\nRocket Lab
\nOverweight (Cantor)
\n$122.00<\/p>\n